* Xenetic Biosciences Inc reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -69 cents. The lone analyst forecast for the quarter was for a loss of 14 cents per share.

* Revenue rose 0.5% to $614.24 thousand from a year ago; analysts expected $750.00 thousand.

* Xenetic Biosciences Inc's reported EPS for the quarter was a loss of 28 cents​.

* The company reported a quarterly loss of $436.67 thousand.

* Xenetic Biosciences Inc shares had fallen by 4.4% this quarter and gained 19.7% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 6.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

This summary was machine generated from LSEG data November 13 at 02:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.14 -0.28 Missed

Jun. 30 2024 -0.83 -0.83 Met

Mar. 31 2024 -0.79 -0.78 Beat

Dec. 31 2023 -0.87 -0.77 Beat